» Articles » PMID: 10706119

APRIL/TRDL-1, a Tumor Necrosis Factor-like Ligand, Stimulates Cell Death

Overview
Journal Cancer Res
Specialty Oncology
Date 2000 Mar 8
PMID 10706119
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

We have examined the activity of a new member of the tumor necrosis factor (TNF) family identified through Expressed Sequence Tag database searching using TNFalpha protein as the search query. We have termed this protein TNF-related death ligand-la (TRDL-1alpha). Traditional cDNA library screening identified two additional splice variants designated TRDL-1beta and TRDL-1gamma that differed from TRDL-1alpha by the deletion of two small regions within the protein coding region. TRDL-1alpha is identical in sequence to the recently described molecule, APRIL, that may induce cell proliferation. We found, however, that purified, FLAG-tagged TRDL-1alpha caused Jurkat cell death with kinetics that paralleled FasL. In vitro binding experiments demonstrated that TRDL-1alpha coprecipitated Fas and HVEM and suggested TRDL-1alpha as an alternate ligand for these receptors. TRDL-1 localized to chromosome 17p13.3 and its expression was widespread in normal tissues. Examination of 48 tumor samples revealed high levels of TRDL-1 expression in several tumors, including those from the gastrointestinal tract. Expression of TRDL-1 in COS-1 cells confirmed membrane association of TRDL-1, typical of TNF family members.

Citing Articles

TNFSF13 insufficiency disrupts human colonic epithelial cell-mediated B cell differentiation.

Ma X, Dawany N, Kondo A, Maurer K, Karakasheva T, Shraim R bioRxiv. 2024; .

PMID: 39386555 PMC: 11463615. DOI: 10.1101/2024.09.23.614260.


Characterization and high-yield production of non--glycosylated recombinant human BCMA-Fc in .

Hou W, Meng X, Wang Y, Mo W, Wu Y, Yu M Eng Life Sci. 2020; 17(2):96-106.

PMID: 32624756 PMC: 6999299. DOI: 10.1002/elsc.201600039.


The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer.

Kampa M, Notas G, Stathopoulos E, Tsapis A, Castanas E Front Oncol. 2020; 10:827.

PMID: 32612943 PMC: 7308424. DOI: 10.3389/fonc.2020.00827.


Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma?.

Xu S, Lam K Cancers (Basel). 2020; 12(4).

PMID: 32340409 PMC: 7226350. DOI: 10.3390/cancers12041045.


Reverse Signaling of Tumor Necrosis Factor Superfamily Proteins in Macrophages and Microglia: Superfamily Portrait in the Neuroimmune Interface.

Lee W, Seo D, Lim S, Suk K Front Immunol. 2019; 10:262.

PMID: 30838001 PMC: 6389649. DOI: 10.3389/fimmu.2019.00262.